(E)-4-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)benzonitrile | 127034-07-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-4-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)benzonitrile
• 英文别名: 4-[(E)-3-(3,4,5-trimethoxyphenyl)-3-oxoprop-1-enyl]benzonitrile；4-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-enyl]benzonitrile
• CAS: 127034-07-5
• 化学式: C₁₉H₁₇NO₄
• 分子量: 323.348
• InChiKey: DYKSHMPYOXQOCR-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  68.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-4-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)benzonitrile 在 吡啶 、 aluminum (III) chloride 、 盐酸羟胺 、 溶剂黄146 、 三乙胺 、 锌 作用下， 以 四氢呋喃 、 乙酸丁酯 、 异丙醇 为溶剂， 反应 42.0h， 生成 N-(4-{3-(4-[5-(3,4,5-trimethoxyphenyl)isoxazol-3-yl]phenyl)-1,2,4-thiadiazol-5-yl}phenyl)-4-nitrobenzamide
  参考文献：
  名称：

  Synthesis and Anticancer Activity of Amide Derivatives of 1,2-Isoxazole Combined 1,2,4-Thiadiazole

  摘要：

  A series of amide derivatives of 1,2-isoxazole combined with 1,2,4-thiadiazole are synthesized 11a-11j. Their chemical structures are confirmed by H-1 and C-13 NMR, and mass spectra. The products are tested for their anticancer activity against four types of human cancer cell lines, including MCF-7 (breast), A549 (lung), Colo-205 (colon), and A2780 (ovarian). Etoposide is used as a positive control. Most of the compounds show good anticancer activity. The compounds 11b, 11c, 11d, 11e, 11g, and 11j demonstrate more potent activity than etoposide.

  DOI：

  10.1134/s1070363219020257
• 作为产物：
  描述：

  3',4',5'-三甲氧基苯乙酮 、 4-氰基苯甲醛 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 (E)-4-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)benzonitrile
  参考文献：
  名称：

  多聚甲醛和水原位生成二氢的钌催化共轭氢化α,β-烯酮

  摘要：

  尽管使用 Noyori 的 Ru 双功能系统可以实现 α,β-烯酮向烯丙醇的高度选择性氢化，但在不接触 C=O 键的情况下选择性还原 α,β-烯酮中的 C=C 键仍然缺乏通用、简单、高效的程序。研究了钌催化的各种α,β-烯酮以高选择性共轭氢化成饱和酮。该程序最重要的特点是由多聚甲醛（或福尔马林）和水原位产生的氢气用作还原剂。

  DOI：

  10.1002/ejoc.201403359

文献信息

• Ruthenium-Catalyzed Conjugate Hydrogenation of α,β-Enones by in situ Generated Dihydrogen from Paraformaldehyde and Water
  作者：Wanfang Li、Xiao-Feng Wu

  DOI：10.1002/ejoc.201403359

  日期：2015.1

  Notwithstanding that the highly selective hydrogenation of α,β-enones to allylic alcohols can be realized by using Noyori's Ru bifunctional system, the selective reduction of the C=C bonds in α,β-enones without touching the C=O bonds still lacks a general, simple, and efficient procedure. Ruthenium-catalyzed conjugate hydrogenation of various α,β-enones to saturated ketones with high selectivity was investigated

  尽管使用 Noyori 的 Ru 双功能系统可以实现 α,β-烯酮向烯丙醇的高度选择性氢化，但在不接触 C=O 键的情况下选择性还原 α,β-烯酮中的 C=C 键仍然缺乏通用、简单、高效的程序。研究了钌催化的各种α,β-烯酮以高选择性共轭氢化成饱和酮。该程序最重要的特点是由多聚甲醛（或福尔马林）和水原位产生的氢气用作还原剂。
• [EN] NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER<br/>[FR] MODULATEURS DE RÉCEPTEURS NUCLÉAIRES ET LEUR UTILISATION POUR LE TRAITEMENT ET LA PRÉVENTION D'UN CANCER
  申请人：US HEALTH

  公开号：WO2012174436A1

  公开（公告）日：2012-12-20

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  本文披露了一些化合物，它们是核受体调节剂，可以作为雄激素受体的拮抗剂，例如，公式I的化合物：其中R1至R5和X1至X5如本文所述，以及其药用盐、溶剂化合物和立体异构体。还披露了包括这些化合物的药物组合物，以及使用方法和治疗癌症，包括前列腺癌、其他核受体介导的癌症和其他疾病的方法。
• Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans
  作者：D. Batovska、St. Parushev、A. Slavova、V. Bankova、I. Tsvetkova、M. Ninova、H. Najdenski

  DOI：10.1016/j.ejmech.2006.08.012

  日期：2007.1

  A large series of chalcones were synthesized and studied for activity against Candida albicans. The SAR analysis showed that the antifungal activity was highly dependent on the substitution pattern of the aryl rings and correlated to a large extent with the ability of compounds to interact with sulfhydryl groups. The most active were the hydroxylated chalcones as their activity related to the location

  合成了大量查耳酮，并研究了其对白色念珠菌的活性。SAR分析表明，抗真菌活性高度依赖于芳基环的取代方式，并在很大程度上与化合物与巯基相互作用的能力有关。最具活性的是羟基化查耳酮，因为它们的活性与芳基环B中酚基的位置有关，如下所示：o-OH> p-OH约为3,4-di-OH> m-OH。获得的这些相关性和其他相关性极大地有助于设计抗候选查耳酮。
• NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER
  申请人：The U.S.A. as represented by the Secretary, Department of Health and Human Services

  公开号：EP3333153A1

  公开（公告）日：2018-06-13

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  所公开的化合物是核受体调节剂，可作为雄激素受体的拮抗剂，例如，式 I 的化合物： 其中 R1 至 R5 和 X1 至 X5 如本文所述，以及其药学上可接受的盐、溶剂和立体异构体。此外，还公开了包含此类化合物的药物组合物，以及使用方法和癌症（包括前列腺癌、其他核受体介导的癌症和其他疾病）的治疗方法。
• Nuclear receptor modulators and their use for the treatment and prevention of cancer
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10737995B2

  公开（公告）日：2020-08-11

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  所公开的化合物是核受体调节剂，可作为雄激素受体的拮抗剂，例如，式 I 的化合物： 其中 R1 至 R5 和 X1 至 X5 如本文所述，以及其药学上可接受的盐、溶剂和立体异构体。此外，还公开了包含此类化合物的药物组合物、使用方法以及癌症（包括前列腺癌）、其他核受体介导的癌症和其他疾病的治疗方法。